Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

MicroCloud Hologram Announced Launch of A Holographic Brain-Computer Interface(BCI) Data Acquisition System

 MicroCloud Hologram Inc. (NASDAQ: HOLO) ("HOLO" or the "Company"), a Hologram Digital Twins Technology provider, today announced the launch of its holographic BCI (Brain-Computer Interface) data acquisition system.
byCharles Gross
January 26, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

 MicroCloud Hologram Inc. (NASDAQ:HOLO) (“HOLO” or the “Company”), a Hologram Digital Twins Technology provider, today announced the launch of its holographic BCI (Brain-Computer Interface) data acquisition system. The system is the result of the Company’s independent research and development, which is conducive to further improving the Company’s intellectual property protection system, maintaining its technological leadership, and enhancing its core competitiveness.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Short Interest Sector Focus: Energy Sector

By Christopher Sappo
Today, 11:45 PM
As of the close of business on Wednesday, 10/12, we captured the Top 10 Highest Short Interest % stocks within the Energy Sector. The average short interest for stocks within the Energy sector stands at 2.79%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.  

BTU

Read More

AstraZeneca, Daiichi Sankyo Say ENHERTU Demonstrated ‘clinically meaningful and durable response’ In Patients With HER2-Positive Advanced Gastric Cancer In DESTINY-Gastric02 Phase II Trial

By Benzinga Newsdesk
Today, 11:45 PM
Detailed results from the positive DESTINY-Gastric02 Phase II trial showed that ENHERTU®(fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibodyDetailed results from the positive DESTINY-Gastric02 Phase II trial showed that ENHERTU®(fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo

AZN